(Total Views: 100)
Posted On: 04/28/2025 2:11:55 PM
Post# of 594
I cut and paste the NewsRamp stock review.....
https://newsramp.com/curated-news/united-heal...a3f936d8aa
UHP's CelluSTAT Hemostatic Gauze has met safety requirements for a Class III device, potentially positioning the company for increased market competitiveness.
FDA requested additional tests for UHP's IDE application, confirming sterility and biocompatibility of the product, essential for commencing clinical study enrollment.
UHP's natural hemostatic agent aims to improve patient outcomes by controlling bleeding, seeking approval to access the surgical market for better medical care.
UHP's innovative CelluSTAT Hemostatic Gauze offers a promising solution to manage mild to moderate bleeding, potentially revolutionizing medical treatment methods.
This summary is compelling IMO!
https://newsramp.com/curated-news/united-heal...a3f936d8aa
UHP's CelluSTAT Hemostatic Gauze has met safety requirements for a Class III device, potentially positioning the company for increased market competitiveness.
FDA requested additional tests for UHP's IDE application, confirming sterility and biocompatibility of the product, essential for commencing clinical study enrollment.
UHP's natural hemostatic agent aims to improve patient outcomes by controlling bleeding, seeking approval to access the surgical market for better medical care.
UHP's innovative CelluSTAT Hemostatic Gauze offers a promising solution to manage mild to moderate bleeding, potentially revolutionizing medical treatment methods.
This summary is compelling IMO!
(0)
(0)
